Alexithymia is related to a higher severity of substance use disorders (SUD); however, few longitudinal studies have been performed on how alexithymia impacts treatment outcomes. This study aims to evaluate alexithymia as a factor that could influence retention and the time of the first relapse in a one-year follow-up in an outpatient treatment center for SUD. In total, 126 SUD outpatients (74.60% males; M age = 43.71, SD = 14.61 years) were evaluated at baseline with an AdHoc questionnaire for sociodemographic variables, the European Addiction Severity Index (EuropASI), the Semi-structured Clinical Interview for Axis I and Axis II Disorders of the DSM-IV, and the Toronto Alexithymia Scale (TAS-20). The prevalence of alexithymia was 41.3% and the mean score of TAS-20, was 57.27 (SD = 12.84). At baseline, alexithymia was related to a lower education level, cannabis use disorder, the psychological item of EuropASI, and mood spectrum disorders. In the Kaplan-Meier analysis, SUD patients with alexithymia were in treatment for less time and presented earlier relapses than non-alexithymic patients. In the Cox regression, alexithymia was only associated with less time in treatment. Therefore, alexithymia may have an important role in the outcomes of SUD treatment, and hence, therapeutic approaches for SUD that cover emotional impairments associated with alexithymia should be investigated and developed.

Alexethymia与物质滥用障碍（SUD）的严重程度有关；然而，很少有关于运动障碍如何影响治疗结果的纵向研究。这项研究旨在评估运动障碍作为可能会影响SUD门诊治疗中心一年随访中保留率和首次复发时间的因素。总共126名SUD门诊病人（男性74.60％; M年龄= 43.71，SD （= 14.61岁）在基线时使用AdHoc调查表评估了社会人口统计学变量，欧洲成瘾严重性指数（EuropASI），DSM-IV的I型和II型轴半结构性临床访谈以及多伦多Alexithymia量表（ TAS-20）。智力障碍的患病率为41.3％，TAS-20的平均得分为57.27（SD = 12.84）。在基线时，运动障碍与低学历，大麻使用障碍，EuropASI的心理项目以及情绪谱障碍有关。在Kaplan-Meier分析中，SUD伴有运动障碍的患者比非无毒血症的患者接受治疗的时间更少，复发时间更早。在Cox回归中，运动障碍仅与较少的治疗时间有关。因此，运动障碍可能在SUD治疗的结果中起重要作用，